LifeTech Scientific’s Lantval™ Aortic Valve Replacement System has entered China’s NMPA innovative medical device special review pathway. The sutureless surgical valve combines a fully preloaded dry-valve design with self-expanding anchoring, with its pre-market registration clinical study expected to begin next.

A multicenter real-world study of Bausch + Lomb’s enVista Aspire™ and enVista Aspire™ Toric IOLs found strong distance vision and functional intermediate vision, with monocular UIVA of 20/32 or better achieved in 76.6% and 93.0% of eyes, respectively.

Liangyi unveiled three new product lines at CAOS 2026, including a universal positioning arm, a large-bone surgical power system and a high-speed surgical power system reaching 95,000 rpm, further expanding its upstream orthopedic robotics portfolio.

FUTURTEC’s ORTHBOT X knee replacement surgical navigation and positioning system has received CE MDR certification, extending the company’s European-certified orthopedic robotics portfolio from spine surgery into joint replacement.

China’s Class I, II and III device categories may look familiar, but they do not map directly onto U.S. FDA or EU MDR classifications. This guide explains how the NMPA determines device risk, which authority handles each pathway, and what classification means for filing, registration and clinical evidence.

At the recently concluded 93rd China International Medical Equipment Fair (CMEF 2026), surgical robots once again emerged as a focal point.